Skip to main content
Editas Medicine, Inc. logo

Editas Medicine, Inc. — Investor Relations & Filings

Ticker · EDIT ISIN · US28106W1036 LEI · 5299000AON4Q9NT2JE42 US Professional, scientific and technical activities
Open in API
Filings indexed 679 across all filing types
Latest filing 2020-05-07 Earnings Release
Country US United States of America
Listing US EDIT

About Editas Medicine, Inc.

https://www.editasmedicine.com/

Editas Medicine, Inc. is a clinical-stage genome editing company focused on developing transformative medicines for serious diseases using CRISPR technology. The company's mission is to discover, develop, and commercialize durable, precision genomic therapies that can correct the underlying genetic causes of various conditions. Its proprietary platform enables the precise revision, removal, or replacement of DNA. Editas Medicine's research and development pipeline is concentrated on creating both in vivo (in-body) and ex vivo (out-of-body) gene-edited medicines to treat a broad class of diseases, with a focus on rare genetic disorders.

Recent filings

Filing Released Lang Actions
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 7, 2020, reporting the issuance of a press release announcing financial results for the fiscal quarter ended March 31, 2020. The text explicitly states that the press release is furnished as an exhibit and is not "filed" for purposes of Section 18 of the Exchange Act, indicating this document is a current report announcing earnings results rather than the earnings release itself. The document length is 3751 characters, which is relatively short and consistent with an announcement rather than a full report. The content corresponds to an initial announcement of quarterly financial results, which fits the definition of an Earnings Release (ER). However, since the actual press release is furnished as an exhibit and the 8-K itself is a current report announcing it, the best classification is Earnings Release (ER) with high confidence.
2020-05-07 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The specific item reported is Item 5.02, which relates to the departure of a director or certain officers and appointment of certain officers. The text details the resignation of the Chief Medical Officer and subsequent advisory agreement. There is no financial data, earnings information, or report publication mentioned. The document is clearly an announcement of management changes, fitting the Board/Management Information category (MANG). The document length is 3442 characters, which is typical for an 8-K filing of this nature and not a full report. Therefore, the classification is MANG with high confidence.
2020-05-06 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A filing, which is a proxy statement filed pursuant to Section 14(a) of the Securities Exchange Act of 1934. It includes information about the upcoming Annual Meeting, voting instructions, and proposals to be voted on, such as election of directors and approval of executive compensation. The document is titled 'Definitive Additional Materials' related to the proxy statement and does not contain financial statements or detailed financial analysis. It is clearly a proxy solicitation document intended to inform shareholders and solicit their votes for the annual meeting. Therefore, the appropriate classification is Proxy Solicitation & Information Statement (PSI). The document length (6315 characters) and content confirm it is not a brief announcement or a full annual report but a proxy statement material.
2020-04-28 English
DEF 14A
Proxy Solicitation & Information Statement
2020-04-28 English
Regulatory Filings 2020
Regulatory Filings
2020-04-27 English
S-8
Share Issue/Capital Change Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans such as stock incentive plans and employee stock purchase plans. It includes details about the securities to be registered, the plans under which they are offered, and legal and indemnification provisions. It is not a financial report, earnings release, or management discussion, nor is it an announcement of voting results or a proxy statement. It is a capital market filing related to securities registration and employee stock plans, which fits the category of Share Issue/Capital Change filings. The document length is substantial and contains detailed registration information, not just an announcement or certification. Therefore, the appropriate classification is Share Issue/Capital Change (SHA).
2020-02-26 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.